At a glance
ClinicalIndex Comparison RecordN/ACompleted· 30 enrolled
Drug / intervention
Acthardrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Tolerability of Acthar for the Treatment of Multiple Sclerosis Relapses (TAMS)
In Brief
A clinical study evaluating Acthar for Relapsing Remitting Multiple Sclerosis. Completed, enrolled 30 participants across 1 site.
Detailed Summary
Tolerability of Acthar for the Treatment of Multiple Sclerosis Relapses (TAMS)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsing Remitting Multiple Sclerosis
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJun 2014
First PostedOct 2014
Primary CompletionJun 2016
Study CompletionDec 2016
TodayJul 2026
First PostedOct 7, 2014
Enrollment StartJun 1, 2014
Primary CompletionJun 24, 2016
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 11.7 years ago
Interventions
Acthardrug
Is indicated for the treatment of acute exacerbations of multiple sclerosis in adults.